Malignant melanoma in patients treated for psoriasis with PUVA

Photodermatology Photoimmunology and Photomedicine

Volumn 15, Issue 1, 1999, Pages 37-38

  Stern, Robert S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Malignant melanoma; Psoriasis; PUVA

Indexed keywords

PSORALEN;

DRUG EFFECT; HIGH RISK POPULATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUTAGENICITY; PRIORITY JOURNAL; PUVA; RADIATION EXPOSURE; REVIEW; SKIN CANCER; ULTRAVIOLET A RADIATION;

EID: 0032910975     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0781.1999.tb00052.x     Document Type: Review

References (6)

1. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994: 73: 2759-2764.
2. Klecak G, Urbach F, Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol 1997: 37: 174-181.
3. Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. Arch Dermatol 1997: 133: 1530-1533.
4. Roelandts R. Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol 1984: 120: 662-669.
5. Rhodes AR, Stern RS, Melski JW. The PUVA lentigo: analysis of predisposing factors. J Invest Dermatol 1983: 81: 459-463.
6. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997: 336: 1041-1045.